Although Aduhelm has not panned out, there are still a number of medications in clinical development for this devastating form of dementia, including Maryland’s NeuroNascent, Inc., which is developing a new chemical entity that the company hopes will be able to reverse some or all of the dreaded disease deficits, through the production of new neurons. The Rockville-based company’s lead drug candidate, NNI-362 is being developed as a potential Alzheimer’s therapy that actually preclinically demonstrated the ability to produce new neurons.
NeuroNascent Continues to See Positive Clinical Data with Alzheimer’s Therapy
